Connect public, paid and private patent data with Google Patents Public Datasets

Snail, a new marker for tumour invasion and target protein of new antitumoral compounds

Download PDF

Info

Publication number
US20070077590A1
US20070077590A1 US11591826 US59182606A US2007077590A1 US 20070077590 A1 US20070077590 A1 US 20070077590A1 US 11591826 US11591826 US 11591826 US 59182606 A US59182606 A US 59182606A US 2007077590 A1 US2007077590 A1 US 2007077590A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
cadherin
cell
snail
expression
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11591826
Inventor
Amparo Cano Garcia
M' Angele Nieto Toledano
M' Isabel Casteo
Annamaria Locascio
Marta Barrio
Maria Jose Blanco Valderrama
Francisco Perez
Mirna Perez Moreno
Original Assignee
Amparo Cano Garcia
Nieto Toledano M Angele
Casteo M Isabel R
Annamaria Locascio
Barrio Marta G D
Valderrama Maria Jose Blanco F
Perez Francisco P
Perez Moreno Mirna A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Hybridisation probes
    • C12Q1/6883Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Abstract

The Snail transcription factor has been identified as a repressor of the expression of E-cadherin. The expression of Snail induces invasive and metastatic capacity in tumour cells. This invention presents: a new target protein, Snail, for the identification of new antitumoral compounds and a new diagnostic tumour marker, indicative of tissue invasion and metastatic capacity.

Description

    INVENTION SECTOR
  • [0001]
    Biomedicine. Target protein for antitumoral compounds. System for identification of candidates for antitumoral compounds.
  • [0002]
    Tumour invasion and metastasis markers, their use as diagnostic markers of the disease and as a guide to medical professionals in the selection or evaluation of treatments.
  • PRIOR ART
  • [0003]
    The protein E-cadherin has not only been shown to mediate intercellular adhesion of epithelial cells during embryonic development and in adult tissues, but also to be implicated in the phenotypic transformation observed in epithelial tumours during their progression into invasive tumours. In this process of invasion by the tumour cells, expression of the protein E-cadherin is reduced or abolished and this loss is associated with the acquisition of migratory properties. Functional alterations of E-cadherin and/or its associated proteins, catenins, have been associated with de-differentiation and greater aggressivity of tumours [Takeichi, M. Cadherins in cancer: implications for invasion and metastasis. Curr. Op. Cell Biol. 5, 806-811 (1993); Birchmeier, W. & Behrens, J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim. Biophys. Acta 1198, 11-26 (1994)] and have even been seen to be implicated in the transition from adenomas to invasive carcinomas [Perl, A. K., P. Wilgenbus, U. Dahl, H. Semb & Christofori, G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392, 190-193 (1998).]. For all of these reasons, the E-cadherin gene has been considered to be a tumoral invasion suppressor gene [Frixen, U. H., et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol 113, 173-185 (1991); Vleminckx, K., Vakaet, L. J., Mareel, M., Fiers, W. & Van Roy, F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66, 107-119 (1991); Miyaki, M. et al. Increased cell-substratum adhesion, and decreased gelatinase secretion and cell growth, induced by E-cadherin transfection of human colon carcinoma cells. Oncogene 11, 2547-2552 (1995); Llorens, A. et al. Downregulation of E-cadherin in mouse skin carcinoma cells enhances a migratory and invasive phenotype linked to matrix metalloproteinase-9 gelatinase expression. Lab. Invest. 78, 1-12 (1998).] so that the molecular mechanisms which control its expression or function are of the utmost importance in increasing our knowledge of tumour invasion processes.
  • [0004]
    Expression of the E-cadherin gene is regulated by several elements located in the 5′ proximal region of its promoter [Behrens, J., Löwrick, O., Klein, H. L. & Birchmeier, W. The E-cadherin promoter: functional analysis of a GC-rich region and an epithelial cell-specific palindromic regulatory element. Proc. Natl. Acad. Sci. USA 88, 11495-11499 (1991); Ringwald, M., Baribault, H., Schmidt, C. & Kemler, R. The structure of the gene coding for the mouse cell adhesion molecule uvomorulin. Nucleic Acids Res. 19, 6533-6539 (1991); Bussemakers, M. J., Giroldi, L. A., van Bokhoven A. & Schalken, J. A. Transcriptional regulation of the human E-cadherin gene in human prostate cancer cell lines: characterization of the human E-cadherin gene promoter. Biochem. Biophys. Res. Commun. 203, 1284-1290 (1994); Giroldi, L. A. et al. Role of E-boxes in the repression of E-cadherin expression. Biochem. Biophys. Res. Commun. 241, 453-458 (1997)]. Of these, the E-pal element, which contains two E-boxes, has been identified in the E-cadherin promoter in mice (between positions −90 and −70) and is important because it acts as a repressor in normal cells and transformed cells deficient in E-cadherin [Behrens, J., Löwrick, O., Klein, H. L. & Birchmeier, W. The E-cadherin promoter: functional analysis of a GC-rich region and an epithelial cell-specific palindromic regulatory element. Proc. Natl. Acad. Sci. USA 88, 11495-11499 (1991); Hennig, G., Löwrick, O., Birchmeier, W & Behrens, J. Mechanisms identified in the transcriptional control of epithelial gene expression. J. Biol. Chem. 271, 595-602 (1996); Faraldo, M. L., Rodrigo, I., Behrens, J., Birchmeier, W & Cano, A. Analysis of the E-cadherin and P-cadherin promoters in murine keratinocyte cell lines from different stages of mouse skin carcinogenesis. Mol. Carcinog. 20, 33-47 (1997); Rodrigo, I., Cato, A. C. B. & Cano, A. Regulation of E-cadherin gene expression during tumor progression: the role of a new Ets-binding site-and the E-pal element. Exp. Cell Res. 248, 358-371 (1999)]. The transcription factors which interact with this element or in the corresponding region of the promoter of the human cadherin gene [Bussemakers, M. J., Giroldi, L. A., van Bokhoven A. & Schalken, J. A. Transcriptional regulation of the human E-cadherin gene in human prostate cancer cell lines: characterization of the human E-cadherin gene promoter. Biochem. Biophys. Res. Commun. 203, 1284-1290 (1994); Giroldi, L. A. et al. Role of E-boxes in the repression of E-cadherin expression. Biochem. Biophys. Res. Commun. 241, 453-458 (1997)] are unknown.
  • [0005]
    Potential transcription factors which are repressors of the expression of the E-cadherin gene could be of great value in the identification of new antitumoral candidates which act by inhibiting the function of these factors, and consequently the invasive and metastatic process. Furthermore, their presence could be used as markers of tumour spread and malignancy.
  • DESCRIPTION BRIEF DESCRIPTION
  • [0006]
    The transcription factor Snail has been identified as a repressor of the expression of E-cadherin, as it has a direct interaction with the E2 box of the E-pal element of the promoter. The ectopic expression of Snail in epithelial cells induces epithelial-mesenchymal transition and the acquisition of migratory properties concomitant with inhibition of E-cadherin expression and the loss of other epithelial differentiation markers. This invention presents and includes the following:
      • a new target protein for the identification of new antitumoral compounds, and
      • a new marker of tumour invasion and metastasis and its application as a diagnostic marker of the disease and as a guide to medical professionals in the selection or evaluation of treatments.
  • DETAILED DESCRIPTION
  • [0000]
    Snail is a Transcription Factor Which Acts as a Direct Repressor of E-cadherin Expression
  • [0009]
    Identification of transcription factors which interact with the E-pal element was undertaken by means of a one-hybrid approximation using the mouse E-pal sequence (−90/−70) oligomerised to direct the expression of the HIS3 gene of S. cerevisiae as bait and a cDNA gene library of NIH3T3 fused to the GAL4 activation domain as a prey. A total of 130 clones were isolated, capable of interacting with (and directing the transcription of the reporter gene HIS3) the construction containing the native E-pal element; they did not recognise the mutated oligomeric element. This mutated form of the E-pal element contains 2 modified bases (TT instead of GC) which eliminate the E2 box. This mutated form has been described as being responsible for abolishing the repressor effect in the E-cadherin promoter in mice (Hennig, G., Löwrick, O., Birchmeier, W. & Behrens, J. Mechanisms identified in the transcriptional control of epithelial gene expression. J. Biol. Chem. 271, 595-602 (1996); Faraldo, M. L., Rodrigo, I., Behrens, J., Birchmeier, W & Cano, A. Analysis of the E-cadherin and P-cadherin promoters in murine keratinocyte cell lines from different stages of mouse skin carcinogenesis. Mol. Carcinog. 20, 33-47 (1997).
  • [0010]
    Sequentiation of the isolated clones revealed that 49% of them contained inserts which encoded the complete or partial sequence of the mouse Snail cDNA [Nieto, M. A., Bennet, M. F., Sargent, M. G. & Wilkinson, D. G. Cloning and developmental expression of Sna, a murine homologue of the Drosophila snail gene. Development 116, 227-237 (1992); Smith, D. E., Del Amo, F. F. & Gridley, T. Isolation of Sna, a mouse homologous to the Drosophila gene snail and escargot: its expression pattern suggests multiple roles during postimplantation development. Development 116, 1033-1039 (1992)], while one single clone encoded a partial sequence of the mouse Slug cDNA.
  • [0011]
    To determine the effect of Snail as a transcription factor in the context of the proximal region of the E-cadherin promoter (−178/+92), the complete sequence of Snail DNA was subcloned in an expression vector (pcDNA3) and its activity was analysed by cotransfection in two mouse epidermal keratinocyte cell lines, MCA3D and PDV. Both lines had previously been characterised as having a high level of E-cadherin expression and promoter activity [Faraldo, M. L., Rodrigo, I., Behrens, J., Birchmeier, W & Cano, A. Analysis of the E-cadherin and P-cadherin promoters in murine keratinocyte cell lines from different stages of mouse skin carcinogenesis. Mol. Carcinog. 20, 33-47 (1997); Rodrigo,
  • [0012]
    I., Cato, A. C. B. & Cano, A. Regulation of E-cadherin gene expression during tumor progression: the role of a new Ets-binding site and the E-pal element. Exp. Cell Res. 248, 358-371 (1999); Navarro, P. et al. A role for the E-cadherin cell-cell adhesion molecule in tumor progression of mouse epidermal carcinogenesis. J. Cell Biol. 115, 517-533 (1991)]. Cotransfection of Snail in MCA3D cells (FIG. 1A) and PDV (FIG. 1B) produced strong repression of the native E-cadherin promoter (95% and 75%, respectively), but not of the promoter containing the mutated E2 box (FIG. 1). These results confirm those obtained by the one-hybrid screening method and demonstrate that Snail is a direct repressor of the transcription of the E-cadherin gene acting through its binding to the E2 box of the E-pal element.
  • [0000]
    Snail Induces the Fibroblastic Conversion of Epithelial Cells and the Acquisition of Migratory Properties
  • [0013]
    To obtain more information about the role of the Snail protein in the regulation of the E-cadherin gene and its participation in epithelial-mesenchymal transition, it was ectopically expressed in several cell lines. Transient expression of Snail was initially analysed in the keratinocyte lines MCA3D and PDV, which offer the advantage of being able to grow in isolated groups, establishing strong intercellular contacts mediated by E-cadherin even at low density, and exhibit very low cell motility [Navarro, P. et al. A role for the E-cadherin cell-cell adhesion molecule in tumor progression of mouse epidermal carcinogenesis. J. Cell Biol. 115, 517-533 (1991); Lozano, E & Cano, A. Cadherin/catenin complexes in murine epidermal keratinocytes: E-cadherin complexes containing either b-catenin or plakoglobin contribute to stable cell-cell contacts. Cell Adh. Commun. 6, 51-67 (1998); Gómez M., Navarro P. & Cano A. Cell adhesion and tumor progression in mouse skin carcinogenesis: increased synthesis and organization of fibronectin is associated with the undifferentiated spindle phenotype. Invasion & Metastasis 14, 17-26 (1994); Frontelo, P. et al. Transforming growth factor b1 induces squamous carcinoma cell variants with increased metastatic abilities and a disorganized cystoskeleton. Exp. Cell Res. 244, 420-432 (1998)]. The overexpression of Snail eliminated intercellular contacts within the 24-28 hours after transfection in both cell types as a consequence of inhibition of the expression of E-cadherin (FIGS. 2 b and 2 f) and other associated proteins, such as plakoglobin. Simultaneously with these changes, the morphology of the cells transfected with Snail was greatly altered. Abundant membranous prolongations and long filaments resembling filopodia were observed in both cell lines.
  • [0014]
    Stable expression of Snail was carried out in the cell line MDCK, which exhibits a “prototypical” epithelial phenotype and appears as a monolayer in culture. This phenotype does not seem to be affected by expression of the control vector in six independent isolated clones (FIG. 3 a), which maintain the expression of E-cadherin (FIG. 3 b) and plakoglobin (FIG. 3 c) in intercellular contacts. However, stable expression of Snail induces a dramatic conversion to a completely undifferentiated fibroblastic phenotype. MDCK cells transfected with Snail lose the ability to grow as a monolayer and to inhibit by contact. Instead, these cells form overlying networks with extremely long membranous extensions (FIG. 3 d). Analysis of E-cadherin and plakoglobin expression showed the loss of both molecules in MDCK cells transfected with Snail (FIGS. 3 e and f). Additionally, stable expression of Snail in MDCK cells induced a strong migratory behaviour, which was demonstrated by tests of wound-healing in cultures (FIG. 4).
  • [0000]
    Snail is Expressed in Undifferentiated Tumours and in Invasive Regions of Epidermoid Carcinomas
  • [0015]
    Analysis of the endogenous expression of Snail by RT-PCR in a panel of cell lines with varying E-cadherin expression demonstrated an inverse correlation between the expression of both molecules and a relationship between the expression of Snail and their invasive and metastatic capacity (FIG. 5). E-cadherin was observed in the epithelial, non-tumoral MCA 3D cell line and in the P¢V tumoral cell line, which in spite of its tumoral origin showed no invasive or metastatic capacity. However, the presence of Snail was not found in any of the cell lines. In contrast, in the tumour cell lines with invasive and metastatic capacity, HaCa4 and CarB, the absence of E-cadherin is associated with the presence of Snail.
  • [0016]
    Expression of Snail was analysed by in situ hybridisation in epidermoid tumours induced in immunodepressed mice, either by different cell lines or by chemical treatment of the mouse's skin. In both cases, high expression of Snail was observed in undifferentiated tumours (FIGS. 6 f and h) and in zones of invasion in epidermoid carcinomas (FIG. 6 l) which had lost expression of E-cadherin (FIG. 6 k). In contrast, no expression of Snail was detected in non-invasive, well-differentiated tumours (FIGS. 6 b and 6 d).
  • [0017]
    Taken together, these data demonstrate that Snail is a direct repressor of E-cadherin expression, implicated in the epithelial-mesenchymal transition which occurs during tumour invasion. The presence of Snail, therefore, is a new marker of tumour progression, specifically associated with the acquisition of the invasive and metastatic phenotype, which allows it to be used as a diagnostic marker of tumours in humans and as a guide to medical professionals in the selection and evaluation of antitumoral treatments and forms part of this invention.
  • [0018]
    Moreover, these data clearly indicate the direct inductive role of Snail in the acquisition of these characteristics of tumour invasion and metastasis, so that Snail may be considered a target protein for new antitumoral compounds. Experiments to identify new antitumoral candidates can be developed from this protein, based on cell lines transformed by the Snail protein, in which analysis of the regulation of Snail expression by an antitumoral candidate would identify new antitumoral compounds, which form part of this invention. Analysis of the regulation of Snail expression could be carried out by determining the presence or absence of Snail after contact with the antitumoral candidate, or by means of another type of signal inhibiting the Snail function in cells transformed with reporter genes, eg HIS3 and LacZ, which form part of this invention.
  • DESCRIPTION OF THE FIGURES
  • [0019]
    FIG. 1.—Snail represses the activity of the E-cadherin promoter in epithelial cell lines. MCA3D (FIG. 1A) and PDV cells (FIG. 1B) were transfected with the native E-cadherin promoter (wt-178) or with a mutated version (mE-pal) fused to the gene marker CAT in the presence of 1 μg of control vector pcDNA3 or containing Snail. The graph shows the levels of CAT activity of the promoter. Promoter activity is expressed as a measurement relative to that of the native promoter in the presence of the control vector.
  • [0020]
    FIG. 2.—Transient expression of Snail in epidermal keratinocytes induces loss of E-cadherin and plakoglobin and loss of cell-cell adhesion. MCA3D (a-d) and PDV (e-h) cells were transfected with control vector (mock, a,c,e,g) or that containing Snail cDNA (b,d,g,h) and the presence of E-cadherin and plakoglobin was analysed by immunocytochemistry visualised by confocal microscopy after 48 hours.
  • [0021]
    FIG. 3.—Stable transfection of Snail in MDCK epithelial cells induces epithelial-mesenchymal conversion concomitant with the loss of E-cadherin and plakoglobin. Phase contrast images of cells transfected with the control vector (a) and with the vector containing Snail (d). Confocal microscopy images which show expression of E-cadherin (b,e) and plakoglobin (c,f) in control and transfected Snail cells, respectively.
  • [0022]
    FIG. 4.—Snail induces a migratory phenotype in epithelial cells. The migratory behaviour was analysed in an in vitro wound model. MDCK control cultures (mock) or cultures transfected with Snail were scratched with the tip of a pipette and photographs were taken immediately (t=0, a,d) and 10 hours later (b,e).
  • [0023]
    FIG. 5.—Analysis of the endogenous expression of Snail by RT-PCR in a panel of cell lines. The endogenous expression of Snail is inversely correlated with that of E-cadherin in normal and transformed mouse keratinocyte cell lines.
  • [0024]
    FIG. 6.—Snail expression is associated with invasive carcinomas and invasive areas in epidermoid carcinomas. Tumours were induced in nude mice with PDV (a-d) or CarB (e-h) cells or by chemical treatment (i-l). They were analysed by hybridisation in situ with E-cadherin (a,c,e,g,i,k) or Snail (b,d,f,h,j,l) probes. E-cadherin is expressed in differentiated areas of epidermoid carcinomas (a,c,i,k), while there is no expression of Snail in these tumours (b,d,j). Invasive carcinomas do not express E-cadherin (e,g) but do express Snail (f,h). In chemically induced tumours, Snail expression is observed in undifferentiated invasive areas (l), which do not express E-cadherin (k).
  • EXAMPLES Example 1 Isolation of Snail cDNA in Mice Using the One-Hybrid Technique
  • [0025]
    The oligonucleotide which contains the sequence of the E-pal element of the mouse E-cadherin promoter (CD-E) (nucleotides −90 to −70) containing targets for the restriction enzymes SalI in 5′ and XhoI in 3′ was ligated in direct sense for a total of 6 complete repetitions using conventional techniques, isolation in polyacrylamide gels and cloning in pHISi vector (Clontech, Palo Alto, Calif.) which contains the reporter gene HIS3 of S. cerevisiae, and replication elements of yeast, bacteria and appropriate selection genes. In this way, the expression of the HIS3 gene remains under the control of the multimerised E-pal element. Correct insertion of the regulatory sequences was verified by PCR, digestion with appropriate restriction enzymes and sequentiation. The bait vector thus generated was denominated pHIS-E6. The same method was used to generate vectors into which a mutant version of the E-pal element was introduced, also ligated 6 times in direct sense, in which the two central oligonucleotides, GC, were replaced by TT. The mutant bait vector generated was denominated pHIS-mE6. The bait vectors pHIS-E6 and pHIS-mE6 were independently integrated in the chromosomal locus URA3 of the yeast strain YM4271 (Clontech, Palo Alto, Calif.) by the usual techniques for transformation and selection of stable strains which maintain growth in the presence of 20 mM 3-aminotriazole (3AZT). The strains selected were denominated E-pal HIS3 (native E-pal construct) and ME-pal HIS3 (mutated E-pal construct). The yeast strain E-pal HIS3 was subjected to transformation with a commercial gene library of cDNA from NIH3T3 cells which contains different inserts of cDNA fused to the GAL4 activation domain in the pACT2 vector (Clontech, Palo Alto, Calif.), previously amplified to obtain a titre of 3×106 independent clones using conventional techniques. Transformant yeasts were selected for their ability to grow in the absence of Histidine and in the presence of 20 mM 3ATZ, and 300 independent clones were isolated. The plasmids containing the different sequences of cDNA were isolated from the transformant yeasts and were later used to transform E. coli (DH5α strain), recovering 221 independent E. coli clones, from which the corresponding plasmids were isolated. To eliminate false positives, the 221 plasmids were independently introduced in parallel into the previously generated yeast strains containing the HIS3 gene under the control of the wild E-pal element (E-pal HIS3 strain) or mutated E-pal (mE-pal HIS3 strain), selecting those plasmids which conferred growth in the absence of histidine and leucine and in the presence of 20 mM 3ATZ exclusively in the strain E-pal His3; the total number selected was 130. Inserts of these plasmids were initially analysed using digestion with various restriction enzymes and sequenced in an automatic sequencer. The sequences obtained were analysed in cDNa databanks using the BLAST/FASTA programme. 49% of the clones identified encoded the total or partial mouse Snail cDNA sequence.
  • Example 2 Transitory Stable Transfection of mSnail in Epithelial Cells
  • [0026]
    The complete mouse Snail cDNA sequence (mSnail) contained in one of the clones identified in the one-hybrid screening was isolated from the pACT2 vector by digestion with the restriction enzymes EcoRIy HindIII and subcloned in the EcoRI/HindIII sites of the pcDNA3 vector (Invitrogene), which contains the neo gene conferring resistance to the antibiotic G418 and was sequenced at both ends. The vector thus generated was denominated pcDNA3-mSnail.
  • [0027]
    The mouse E-cadherin promoter construct, −178, which contains the gene sequences −178 to +92 pb fusioned to the CAT reporter gene (Chloramphenicol Acetyl Transferase), and the mEpal construct (in which the two central GC nucleotides of the E-pal element were mutated by TT) have been described previously [Behrens, J., Löwrick, O., Klein, H. L. & Birchmeier, W. The E-cadherin promoter: functional analysis of a GC-rich region and an epithelial cell-specific palindromic regulatory element. Proc. Natl. Acad. Sci. USA 88, 11495-11499 (1991); Hennig, G., Löwrick, O., Birchmeier, W & Behrens, J. Mechanisms identified in the transcriptional control of epithelial gene expression. J. Biol. Chem. 271, 595-602 (1996); Faraldo, M. L., Rodrigo, I., Behrens, J., Birchmeier, W & Cano, A. Analysis of the E-cadherin and P-cadherin promoters in murine keratinocyte cell lines from different stages of mouse skin carcinogenesis. Mol. Carcinog. 20, 33-47 (1997)] and were provided by Dr J. Behrens.
  • [0028]
    a) Analysis of the Activity of the E-Cadherin Promoter.
  • [0029]
    MCA3D AND PDV cells were seeded at subconfluence (3×105 cells/6 cm diameter plate, P-60) in HamF12 growth medium containing 10% foetal bovine serum (Gibco) and incubated for 24 hours at 37° C. in an incubator containing 5% CO2 with a humidity of 95%. The medium was then replaced by fresh DMEM medium with 10% foetal bovine serum and kept in the incubator for a further 6 hours. The cultures underwent transfection using Lipofectamin Plus (Life Technologies), following the supplier's instructions, using 2.5 μg of construct −178, mE-pal or the control vector pCATbasic (with no promoter sequences) (Promega) and in the presence of 1 μg of pcDNA3-mSnail or the empty pcDNA3 plasmid. As an additional control, the activity of the E-cadherin promoter constructs was compared with that of the vector pCAT-control (Promega) containing the CAT reporter gene under the control of the SV-40 promoter, and thus the cells were transfected in parallel with this vector. Efficiency of transfection was analysed by cotransfection in all the cultures with 2.5 μg of the CMV-Luc plasmid which; contains the luciferase reporter gene under the control of the cytomegalovirus promoter. Twenty-four hours after transfection the medium was discarded and after washing with PBS the cells were collected by gently scraping the plates and were centrifuged (2000 rpm for 4 minutes). Extracts were obtained by resuspending the cellular pellet in 100 μl of a buffer containing 10 mM phosphate pH 8.0 and subjected to 4 cycles of freezing in liquid N2-thawing at 37° C. Luciferase activity was initially determined in aliquots of 5 μl using a commercial kit and a luminometer. Aliquots of the different extracts containing equivalent luciferase activities were analysed for CAT activity, using C14-chloramphenicol (Amersham) as substrate and Acetyl-CoA (Sigma) as cofactor, following the method described previously [Faraldo, M. L., Rodrigo, I., Behrens, J., Birchmeier, W & Cano, A. Analysis of the E-cadherin and P-cadherin promoters in murine keratinocyte cell lines from different stages of mouse skin carcinogenesis. Mol. Carcinog. 20, 33-47 (1997); Rodrigo, I., Cato, A. C. B. & Cano, A. Regulation of E-cadherin gene expression during tumor progression: the role of a new Ets-binding site and the E-pal element. Exp. Cell Res. 248, 358-371 (1999)]. The CAT activity obtained in MCA3D and PDV cells for the −178 construct of the native E-cadherin promoter was 70% and 50%, respectively, of that of the pCAT-SV40 vector. The CAT activities obtained were normalised to that obtained with the −178 construct in the presence of the empty pcDNA3 vector in each cell line. Transfection assays were performed in equivalent duplicate cultures of each of the cell lines for all the experimental conditions analysed.
  • [0030]
    b) The Effect of the Expression of mSnail in the Cell Phenotype and the Expression of Epithelial Markers
  • [0031]
    Transient transfections were performed with 2 μg of mSnail (pcDNA3-mSnail vector) and “mock” controls (empty pcDNA3 vector) in mouse keratinocyte lines MCA3D and PDV, following the procedure described previously, except that the cells were seeded on circular coverslips (1.2 cm in diameter) placed on top of the P-60 plates. At 24 and 48 hours after transfection, the glass plates corresponding to the two experimental conditions of each cell line were fixed with methanol (−20° C.) for 30 s, and were analysed for E-cadherin and plakoglobin expression by immunofluorescence [Navarro, P. et al. A role for the E-cadherin cell-cell adhesion molecule in tumor progression of mouse epidermal carcinogenesis. J. Cell Biol. 115, 517-533 (1991)]. The images were analysed using a confocal microscope (Leica).
  • [0032]
    Stable transfections of mSnail and “mock” control were carried out on the MDCK epithelial line, grown in DMEM medium, 10% foetal bovine serum, in parallel cultures and following the protocol described previously. Between 48 and 72 hours after transfection, when the cultures reached confluence, the medium was changed for fresh medium and 400 μg/ml of G418 were added, selecting the cells resistant to G418 after 2-3 weeks of growth in the presence of the antibiotic. The total population generated (the “pool”) in both types of culture (mSnail and mock) was collected, and independent clones were obtained by dilution. To do this, 100 cells of each type of population were seeded on P-100 plates (10 cm diameter) and grown in DMEM medium, 10% foetal bovine serum and 400 μg/ml of G418. Independent colonies resistant to G418 were obtained after a further 2-3 weeks, and these were isolated by trypsinisation using cloning cylinders (internal diameter 5 mm) and amplified by successive passages on culture plates of increasing size (T6→F12.5→F25→F75), maintaining antibiotic pressure in all phases of the culture. A total of 10 independent clones were isolated from the mSnail transfection and 6 independent clones from the mock transfection. The different clones were analysed for E-cadherin and plakoglobin expression by immunofluorescence (confocal microscope analysis) and immunotransference, and for mSnail expression by RT-PCR after extraction of the RNA-polyA+ of the different clones and the use of appropriate amplimers to amplify a fragment of 388 base pairs, in accordance with the mSnail cDNA sequence.
  • Example 3 Obtaining Tumours
  • [0033]
    a) Tumours Induced in Immunodepressed Mice by Cell Lines.
  • [0034]
    Tumours were induced in 8-week-old athymic male nu/nu mice of the BalC strain by subcutaneous injection of PDV, HaCa4 or CarB cells, as described previously [Navarro, P. et al. A role for the E-cadherin cell-cell adhesion molecule in tumor progression of mouse epidermal carcinogenesis. J. Cell Biol. 115, 517-533 (1991)]. The different cell lines grew to confluence in F75 bottles, and were trypsinised and resuspended in phosphate buffered saline (PBS) at a density of 1×107 cells/ml in PBS. The cells were subcutaneously injected into both flanks of each mouse (1×106 cells/injection site) using insulin syringes and 25 gauge hypodermic needles. Usually 3 animals were inoculated for each cell line (6 injection sites/line). The animals were obtained from the IFA-CREDO production unit (France) and were kept in sterile conditions in the installation specifically intended for such animals in the animal house of the Instituto de Investigaciones Biomédicas (IIB) in accordance with the centre's regulations for animal handling. The injected animals were observed 3 times a week; the appearance of tumours was determined by visual inspection and measurement of their size was done by caliper. The animals were sacrificed by asphyxia in ether when the external diameter of the tumours reached 1.5-2.0 cm. The tumours were removed, a fraction was fixed in formaldehyde for subsequent histological analysis, and the remainder was immediately frozen in isopentane directly cooled in a bath of liquid nitrogen or embedded in OCT (Tissue Tek). The samples were stored at −70° C. for later use.
  • [0035]
    b) Induction of Tumours in Mouse Skin by Chemical Carcinogenesis.
  • [0036]
    Tumours were induced in the dorsal skin of 8-10-week-old BalC mice obtained from the production unit of the IIB animal house, using the two-stage DMBA/TPA protocol as described [Cano, A. et al. Expression pattern of the cell adhesion molecules E-cadherin, P-cadherin and integrin is altered in pre-malignant skin tumors of p53-deficient mice. Int. J. Cancer 65, 254-262 (1996)]. One week before the start of the experiment, the backs of the animals (20 in total) were shaved, after which a single dose of the carcinogen dimethylben(z)anthracene (DMBA) at a concentration of 50 μg/ml dissolved in acetone was applied. A week later, the promotion was begun by topical application of phorbol tetradecanoylphorbolacetate at a concentration of 50 μg/ml dissolved in ethanol. The TPA was applied every 3 days for a total of 30 weeks. The animals were kept under weekly observation for a total of 50 weeks. At the end of 10 weeks of treatment with TPA the appearance of the first papilloma-type tumours was detected, and these continued to appear throughout the treatment and subsequently, at an average rate of 5-6 tumours per mouse. A small proportion of the papillomas (5%) progressed to carcinomas after the end of the TPA treatment. The animals were sacrificed at different intervals and the tumours were extracted and frozen as previously described.

Claims (7)

1.-12. (canceled)
13. A method of treatment of a pathological process, characterized by the capacity to invade tissues or to metastasize other tissues in a patient in need of said treatment, by administering a therapeutically effective amount of a compound obtained by the steps of:
a. adding said compound to transformed cells which express the diagnostic marker Snail;
b. determining at least one of the reduction or total elimination of the ability to express said diagnostic marker in the transformed cells; and
c. selecting said compound for the treatment of tumor invasion and metastasis if said transformed cells present a reduction or total elimination of Snail expression.
14. The method according to claim 13, wherein said pathological process is an epithelial tumor.
15. A method of treatment of a pathological process, characterized by the capacity to invade tissues or-to metastasize other tissues, in a patient in need of said treatment, by administering a therapeutically effective amount of a compound obtained by the steps of:
a. transforming the yeast strains with the pACT2-mSnail vector, which contains the complete sequence of Snail cDNA in the presence and absence of said compound,
b. determining the growth of transformed yeasts from the strain which expresses the HIS3 gene under the control of native E-pal in the absence of histidine and leucine and in the presence of 3ATZ,
c. determining the inhibitory effect of said compound in yeasts transformed by pACT2-mSnail (mutated Snail) on yeast strains which express the HIS3 gene under control of the native E-pal in the absence of histidine and leucine and in the presence of 3ATZ,
d. and selecting said compound for treatment of tumor invasion and metastasis provided said S. cerevisiae strain cells present a reduction or a total elimination in their growth capacity.
16. The method according to claim 15, wherein said pathological process ia an epithelial tumor.
17. A method of treatment of a pathological process, characterized by the capacity to invade tissues or to metastasize other tissues in a patient in need of said treatment, by administering a therapeutically effective amount of a compound obtained by the steps of:
a. transforming the yeast strains with the pACT2-mSnail vector, which contains the complete Snail cDNA sequence, in the presence and absence of said compound;
b. determining β-galactosidase activity of transformed yeasts from the strain which expresses the LacZ gene under the control of native E-pal.
c. determining the absence of inhibitory effect of said compound in the yeasts transformed by pACT2-mSnail in yeast strains which express the LacZ gene under the control of mutated E-pa; and
d. selecting said compound for the treatment of tumor invasion and metastasis provided said S. cerevisiae strain cells present a positive detection of β-galactosidase activity.
18. The method according to claim 17, wherein said pathological process is an epithelial tumor.
US11591826 1999-07-01 2006-11-02 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds Abandoned US20070077590A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ESP9901466 1999-07-01
ES9901466A ES2161612B1 (en) 1999-07-01 1999-07-01 Method for identifying a compound which inhibits the repressor function of Snail.
US09806445 US6617121B1 (en) 1999-07-01 2000-06-27 Snail, new tumoral progression marker and target protein of new antitumoral compounds
PCT/ES2000/000226 WO2001002860A1 (en) 1999-07-01 2000-06-27 Snail, new tumoral progression marker and target protein of new antitumoral compounds
US10461256 US7794930B2 (en) 1999-07-01 2003-06-13 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds
US11591826 US20070077590A1 (en) 1999-07-01 2006-11-02 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11591826 US20070077590A1 (en) 1999-07-01 2006-11-02 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10461256 Division US7794930B2 (en) 1999-07-01 2003-06-13 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds

Publications (1)

Publication Number Publication Date
US20070077590A1 true true US20070077590A1 (en) 2007-04-05

Family

ID=8309058

Family Applications (6)

Application Number Title Priority Date Filing Date
US09806445 Expired - Fee Related US6617121B1 (en) 1999-07-01 2000-06-27 Snail, new tumoral progression marker and target protein of new antitumoral compounds
US10461256 Expired - Fee Related US7794930B2 (en) 1999-07-01 2003-06-13 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds
US11591717 Abandoned US20070053891A1 (en) 1999-07-01 2006-11-02 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds
US11591826 Abandoned US20070077590A1 (en) 1999-07-01 2006-11-02 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds
US11591825 Expired - Fee Related US7482126B2 (en) 1999-07-01 2006-11-02 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds
US11599664 Expired - Fee Related US7482159B2 (en) 1999-07-01 2006-11-15 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US09806445 Expired - Fee Related US6617121B1 (en) 1999-07-01 2000-06-27 Snail, new tumoral progression marker and target protein of new antitumoral compounds
US10461256 Expired - Fee Related US7794930B2 (en) 1999-07-01 2003-06-13 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds
US11591717 Abandoned US20070053891A1 (en) 1999-07-01 2006-11-02 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11591825 Expired - Fee Related US7482126B2 (en) 1999-07-01 2006-11-02 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds
US11599664 Expired - Fee Related US7482159B2 (en) 1999-07-01 2006-11-15 Snail, a new marker for tumour invasion and target protein of new antitumoral compounds

Country Status (7)

Country Link
US (6) US6617121B1 (en)
CA (1) CA2383943A1 (en)
DE (2) DE60016548D1 (en)
DK (1) DK1109021T3 (en)
EP (1) EP1109021B1 (en)
ES (3) ES2161612B1 (en)
WO (1) WO2001002860A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2451351A1 (en) 2001-06-22 2003-01-03 Burkhard Jansen A method for diagnosing a person having multiple sclerosis
ES2195751B1 (en) * 2001-11-27 2005-04-01 Consejo Superior De Investigaciones Cientificas Transgenic non-human mammals as models for human diseases with stem cell origin.
US20050089896A1 (en) 2003-02-18 2005-04-28 Roy Frans V. Method to control tumor progression and invasiveness
DE60327056D1 (en) * 2002-02-20 2009-05-20 Vlaams Interuniv Inst Biotech A process for the control of tumor progression and invasiveness
WO2004065602B1 (en) * 2003-01-17 2004-09-23 Univ Madrid Autonoma Method of identifying the epithelial-mesenchymal transition of mesothelial cells (emtmc) and identifying emtmc-modulating compounds, pharmaceutical compositions and use thereof in the diagnosis and treatment of diseases associated with emtmc
WO2004086038A3 (en) * 2003-03-28 2005-01-06 Inst Curie A method for screening compounds having the capacity to control tumor cell invasion or metastasis using constitutively active akt
US20060003956A1 (en) * 2004-03-03 2006-01-05 Casadome David O Materials and methods for the derepression of the E-cadherin promoter
ES2301268B1 (en) * 2004-10-25 2009-05-01 Centro De Investigacion Biomolecular Aplicada Salamanca, S.L. Use of the Slug gene or its products of replication, transcription or expression in the identification, diagnosis, prevention or treatment of cancer spread and / or development of metastasis.
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors
DE602006016085D1 (en) * 2005-03-16 2010-09-23 Genentech Inc Biological marker for the predictive-appeal of cancer on inhibitors of the kinase of the receptor for epidermal growth factor
US20100061973A1 (en) * 2005-07-28 2010-03-11 Isidro Sanchez-Garcia Graded Expression of Snail as Marker of Cancer Development and DNA Damage-Based Diseases
WO2007025231A3 (en) * 2005-08-26 2007-10-04 Univ Pennsylvania Methods using snail transcriptional repressor
GB0602063D0 (en) 2006-02-02 2006-03-15 Univ Manchester Cell Culture
WO2008127719A1 (en) * 2007-04-13 2008-10-23 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to kinase inhibitors
WO2009045389A3 (en) * 2007-10-03 2009-07-02 Elizabeth A Buck Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2010540960A (en) * 2007-10-03 2010-12-24 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Biological markers predictive of anticancer response to insulin-like growth factor-1 receptor kinase inhibitors
JP2012519170A (en) * 2009-02-26 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー insitu method for monitoring the emt status of tumor cells in vivo
CA2783665A1 (en) * 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547432A (en) * 1984-07-31 1985-10-15 The United States Of America As Represented By The United States Department Of Energy Method of bonding silver to glass and mirrors produced according to this method
US5241471A (en) * 1989-12-20 1993-08-31 General Electric Cgr S.A. Method of multi-scale reconstruction of the image of the structure of a body at an increased speed
US5980666A (en) * 1995-02-03 1999-11-09 Saint-Gobain Vitrage Process for manufacturing laminated glass window intended for automobiles and capable of reflecting infrared rays
US6972065B1 (en) * 1999-09-29 2005-12-06 Ip2H Ag Process for production of a dielectric multi-layered reflecting coating

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002002A1 (en) * 1994-07-08 1996-01-25 Schalken Jack A Assay for increased invasiveness of epithelial cells
WO1999020168A3 (en) * 1997-10-17 1999-07-01 Univ Otago Germline mutations in the e-cadherin gene and method for detecting predisposition to cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547432A (en) * 1984-07-31 1985-10-15 The United States Of America As Represented By The United States Department Of Energy Method of bonding silver to glass and mirrors produced according to this method
US5241471A (en) * 1989-12-20 1993-08-31 General Electric Cgr S.A. Method of multi-scale reconstruction of the image of the structure of a body at an increased speed
US5980666A (en) * 1995-02-03 1999-11-09 Saint-Gobain Vitrage Process for manufacturing laminated glass window intended for automobiles and capable of reflecting infrared rays
US6972065B1 (en) * 1999-09-29 2005-12-06 Ip2H Ag Process for production of a dielectric multi-layered reflecting coating

Also Published As

Publication number Publication date Type
ES2234619T3 (en) 2005-07-01 grant
ES2161612A1 (en) 2001-12-01 application
US7794930B2 (en) 2010-09-14 grant
EP1109021B1 (en) 2004-12-08 grant
US20040037832A1 (en) 2004-02-26 application
US20070053891A1 (en) 2007-03-08 application
WO2001002860A1 (en) 2001-01-11 application
ES2161655A1 (en) 2001-12-01 application
US6617121B1 (en) 2003-09-09 grant
DE60016548D1 (en) 2005-01-13 grant
DK1109021T3 (en) 2005-03-29 grant
US20070054307A1 (en) 2007-03-08 application
DE60016548T2 (en) 2005-12-08 grant
EP1109021A1 (en) 2001-06-20 application
ES2161655B1 (en) 2002-06-01 grant
CA2383943A1 (en) 2001-01-11 application
US20070065450A1 (en) 2007-03-22 application
US7482126B2 (en) 2009-01-27 grant
US7482159B2 (en) 2009-01-27 grant
ES2161612B1 (en) 2002-06-01 grant

Similar Documents

Publication Publication Date Title
Tsuji et al. Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth
James et al. Structure of the murine homeobox gene cdx-2. Expression in embryonic and adult intestinal epithelium.
Chen et al. A transcriptional partner for MAD proteins in TGF-β signalling
Cordon-Cardo et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas
Du et al. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma
Hu et al. Mammalian homologs of seven in absentia regulate DCC via the ubiquitin–proteasome pathway
Westfall et al. p63: molecular complexity in development and cancer
Hata et al. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor
Qin et al. The transcription factor E2F-1 is a downstream target of RB action.
Burbee et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression
de Alava et al. Molecular biology of the Ewing’s sarcoma/primitive neuroectodermal tumor family
Asher et al. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains
Jeyaseelan et al. A novel cardiac-restricted target for doxorubicin CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes
Liu et al. Mediation of the DCC apoptotic signal by DIP13α
Kim et al. Truncated form of importin α identified in breast cancer cell inhibits nuclear import of p53
Thiébault et al. The netrin-1 receptors UNC5H are putative tumor suppressors controlling cell death commitment
Takash et al. SOX7 transcription factor: sequence, chromosomal localisation, expression, transactivation and interference with Wnt signalling
Richardson et al. Pax-6 is essential for lens-specific expression of zeta-crystallin
Shih et al. Collapsin response mediator protein-1 and the invasion and metastasis of cancer cells
US6703221B1 (en) Notch receptor ligands and uses thereof
Quinn et al. Insulin-like growth factor expression in human cancer cell lines
Dansithong et al. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1
Cacheux et al. Loss-of-function mutations in SIP1 Smad interacting protein 1 result in a syndromic Hirschsprung disease
Du et al. Megakaryoblastic leukemia factor-1 transduces cytoskeletal signals and induces smooth muscle cell differentiation from undifferentiated embryonic stem cells
Rubinfeld et al. The APC protein and E-cadherin form similar but independent complexes with α-catenin, β-catenin, and plakoglobin